Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
2.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Review.

PMID:
19246723
3.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
4.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Review.

PMID:
22207144
5.

Factors associated with clopidogrel nonresponsiveness.

Momary KM, Dorsch MP.

Future Cardiol. 2010 Mar;6(2):195-210. doi: 10.2217/fca.10.1. Review.

PMID:
20230261
6.

Clopidogrel pharmacogenetics and its clinical implications.

Singh M, Thapa B, Arora R.

Am J Ther. 2010 May-Jun;17(3):e66-73. doi: 10.1097/MJT.0b013e3181afbf62. Review.

PMID:
19636246
7.

Antiplatelet treatment of cardiovascular disease: a translational research perspective.

Gurbel PA, Antonino MJ, Tantry US.

Pol Arch Med Wewn. 2008 May;118(5):289-97. Review.

8.

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

Farid NA, Kurihara A, Wrighton SA.

J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Review. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483.

PMID:
19948947
9.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiń≠ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
10.

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.

Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D.

BMJ. 2011 Aug 4;343:d4588. doi: 10.1136/bmj.d4588. Review.

11.

Genetic determinants of on-clopidogrel high platelet reactivity.

Campo G, Miccoli M, Tebaldi M, Marchesini J, Fileti L, Monti M, Valgimigli M, Ferrari R.

Platelets. 2011;22(6):399-407. doi: 10.3109/09537104.2011.579648. Review.

PMID:
21627411
12.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Review.

PMID:
21592545
13.

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?

Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A.

Curr Pharm Des. 2013;19(13):2489-95. Review.

PMID:
23360266
14.

Clopidogrel pharmacogenetics: metabolism and drug interactions.

Close SL.

Drug Metabol Drug Interact. 2011;26(2):45-51. doi: 10.1515/DMDI.2011.002. Review.

PMID:
21819266
15.

[Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor].

Simon T.

Ann Cardiol Angeiol (Paris). 2010 Dec;59 Suppl 2:S42-6. doi: 10.1016/S0003-3928(10)70009-3. Review. French.

PMID:
21237322
16.

The role of the cytochrome P450 polymorphisms in clopidogrel efficacy and clinical utility.

Tousoulis D, Siasos G, Zaromytidou M, Papageorgiou N, Stefanadi E, Oikonomou E, Stefanadis C.

Curr Med Chem. 2011;18(3):427-38. Review.

PMID:
21143117
17.

Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.

Giusti B, Gori AM, Marcucci R, Abbate R.

Expert Opin Drug Metab Toxicol. 2010 Apr;6(4):393-407. doi: 10.1517/17425251003598878. Review.

PMID:
20163283
18.

P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.

Wallentin L.

Eur Heart J. 2009 Aug;30(16):1964-77. doi: 10.1093/eurheartj/ehp296. Review.

19.

Genetic and nongenetic factors influencing the response to clopidogrel.

Notarangelo MF, Bontardelli F, Merlini PA.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S1-7. doi: 10.2459/JCM.0b013e328364bb04. Review.

PMID:
24378836
20.

Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.

Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP.

Pharmacol Ther. 2010 Feb;125(2):249-59. doi: 10.1016/j.pharmthera.2009.10.008. Review.

PMID:
19919843
Items per page

Supplemental Content

Support Center